Skip to main navigation Skip to main content
Home
Menu
  • Join Our Mailing List
  • Contact Us
  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search
 
Enter your keyword(s)

Breadcrumb

  1. BBCIC
  2. Resources
  3. FDA Guidance
  4. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Main navigation

  • About
    • About BBCIC
    • Governance
    • Partners
    • Contact
  • Research
  • News & Events
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 is the final version of a draft guidance for industry originally released in 2012. It provides answers to common questions about the following topics:

  • Biosimilarity or interchangeability.
  • Provisions related to requirement to submit a biologics license application for a “biological product.”
  • Exclusivity.

As stated in the document, the question-and-answer format is intended to promote transparency and facilitate development programs for proposed biosimilar products by addressing questions that may arise in the early stages of development.

Examples of questions addressed in the guidance include:

  • Can a proposed biosimilar product have a different formulation than the reference product?
  • How does FDA interpret the category of “protein (except any chemically synthesized polypeptide)” in the amended definition of “biological product” in section 351(i)(1) of the Public Health Service Act?
  • How can a prospective biosimilar applicant determine whether there is unexpired orphan exclusivity for an indication for which the reference product is licensed?

The full document is available on the FDA website.

Tags:

Why BBCIC?
Learn more about BBCIC and what we do.
Download Our Fact Sheet
Join BBCIC
Help us monitor use, impact, safety, and clinical effectiveness of biologics including biosimilars.
Participate in BBCIC

Contact Us

Send a Message

Address

675 N Washington Street
Suite 220
Alexandria, VA 22314

Phone

703.684.2600

Menu

  • About
  • Research
  • News & Events
  • Resources
  • Search
BBCIC Logo
  • Antitrust
  • Privacy Policy
  • Disclaimer


© 2023 Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)

  • About
    • About BBCIC
      • BBCIC FAQs
    • Governance
      • Board of Managing Directors
      • Communications Committee
      • Steering Committee
      • Science Committee
    • Partners
    • Contact
  • Research
    • Approach
    • Range of Research
    • Our Research
    • Publications & Presentations
  • News & Events
    • BBCIC Calendar
    • BBCIC News
    • Quarterly Newsletters
  • Resources
    • BBCIC Resources
    • FDA Guidance
    • Biosimilars Facts
  • Search